Mumbai-based pharmaceutical company Sudarshan Pharma Industries Limited is likely to remain on investors’ radar after the company announced the allotment of 90 lakh equity shares following the conversion of preferential warrants held by promoter group entities.  

In an exchange filing dated June 12, 2026, the company’s Warrants Committee approved the allotment of 90,00,000 equity shares with a face value of Re 1 each at an issue price of ₹16.983 per share, including a premium of ₹15.983 per share. The allotment was made pursuant to the conversion of 9,00,000 warrants that had originally been issued on a preferential basis to promoter category investors.  

The conversion follows the receipt of the balance 75% warrant subscription amount aggregating to ₹11.46 crore from the allottees. Under SEBI regulations, warrant holders are required to pay 25% of the issue price upfront and the remaining 75% at the time of conversion.  

According to the filing, the equity shares were allotted to promoter group members Vasantrai Hemal Mehta and Sachin Vasantrai Mehta, who converted 4.5 lakh warrants each, resulting in the allotment of 45 lakh equity shares apiece.  

Following the allotment, Sudarshan Pharma’s paid-up equity share capital has increased to ₹24.96 crore, comprising 24.96 crore equity shares of Re 1 each. The company stated that the newly allotted shares will rank pari-passu with the existing equity shares in all respects.  

The company further disclosed that after the allotment, promoter and promoter group shareholding stands at 58.93%, while non-promoter shareholding is 41.07%.  

The development reflects continued promoter participation in the company through capital infusion and may be viewed positively by market participants as a sign of confidence in the company’s growth prospects. Investors will closely watch the stock’s movement in upcoming sessions following the increase in promoter stake and completion of the warrant conversion process.